We are live on ! Find out more
BVF Inc

BVF Inc Portfolio holdings

AUM $3.04B Turnover 10.42%
1-Year Est. Return 129.63%
This Fund
S&P 500
This Quarter Est. Return
-16.69%
1 Year Est. Return
+129.63%
3 Year Est. Return
+531.24%
5 Year Est. Return
+1,335.11%
10 Year Est. Return
+16,856.28%
AUM
$2.07B
AUM Growth
-$429M
Cap. Flow
+$142M
Cap. Flow %
6.88%
Top 10 Hldgs %
44.14%
Holding
87
New
6
Increased
22
Reduced
12
Closed
8
Avg Time Held
2.2 years
Top 10 Avg Time Held
0.7 years
Top 20 Avg Time Held
1 year
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
RPTX icon
1
DELISTED
Repare Therapeutics
RPTX
$116M 5.6%
8,291,988
+2,433,212
+42% +$28.7M
2020 Q2
8 quarters
MLTX icon
2
MoonLake Immunotherapeutics
MLTX
$939M
$114M 5.52%
+21,751,284
New +$137M
2022 Q2
0 quarters
RCUS icon
3
Arcus Biosciences
RCUS
$2.27B
$100M 4.85%
3,960,948
– –
2018 Q1
17 quarters
CGEM icon
4
Cullinan Therapeutics
CGEM
$589M
$96.3M 4.65%
7,509,059
+2,139,600
+40% +$24.3M
2021 Q1
5 quarters
GHRS icon
5
GH Research
GHRS
$1.27B
$92.6M 4.47%
9,275,158
– –
2021 Q2
4 quarters
MRUS icon
6
DELISTED
Merus
MRUS
$92.4M 4.46%
4,081,431
-53,640
-1% -$1.12M
2021 Q4
2 quarters
KYMR icon
7
Kymera Therapeutics
KYMR
$10.2B
$81.5M 3.94%
4,138,758
+552,100
+15% +$12.9M
2020 Q3
7 quarters
XOMA icon
8
DELISTED
Xoma
XOMA
$78.7M 3.8%
3,530,543
– –
2016 Q4
22 quarters
RLAY icon
9
Relay Therapeutics
RLAY
$3.52B
$73.4M 3.55%
4,384,805
-145,800
-3% -$3.12M
2020 Q3
7 quarters
CRNX icon
10
DELISTED
Crinetics Pharmaceuticals
CRNX
$68.6M 3.31%
3,678,947
+675,068
+22% +$13.5M
2021 Q2
4 quarters
KURA icon
11
Kura Oncology
KURA
$675M
$58.7M 2.84%
3,203,783
– –
2017 Q3
19 quarters
ACRS icon
12
Aclaris Therapeutics
ACRS
$555M
$55.5M 2.68%
3,976,543
– –
2021 Q2
4 quarters
CTIC
13
DELISTED
CTI BioPharma
CTIC
$53.3M 2.57%
8,929,690
– –
2015 Q3
27 quarters
EQRX
14
DELISTED
EQRx
EQRX
$49.9M 2.41%
10,648,527
-1,377,043
-11% -$6.21M
2021 Q4
2 quarters
XENE icon
15
Xenon Pharmaceuticals
XENE
$3.69B
$48.6M 2.35%
1,597,966
– –
2014 Q4
30 quarters
IONS icon
16
Ionis Pharmaceuticals
IONS
$4.53B
$47.3M 2.28%
+1,276,574
New +$48.1M
2022 Q2
0 quarters
SNDX icon
17
Syndax Pharmaceuticals
SNDX
$822M
$45.3M 2.19%
2,356,934
-37,780
-2% -$629K
2017 Q4
18 quarters
RVMD icon
18
Revolution Medicines
RVMD
$34.5B
$44M 2.12%
2,255,588
+445,039
+25% +$8.66M
2020 Q1
9 quarters
ITOS icon
19
DELISTED
iTeos Therapeutics
ITOS
$39.7M 1.92%
1,929,201
+529,000
+38% +$12.6M
2022 Q1
1 quarter
IDYA icon
20
IDEAYA Biosciences
IDYA
$2.53B
$38.6M 1.86%
2,794,859
+1,194,300
+75% +$13.3M
2022 Q1
1 quarter
CNTA
21
DELISTED
Centessa Pharmaceuticals
CNTA
$33.6M 1.62%
6,894,345
+5,138,800
+293% +$32.9M
2021 Q4
2 quarters
RLMD icon
22
Relmada Therapeutics
RLMD
$332M
$31.5M 1.52%
1,659,220
+11,820
+0.7% +$258K
2021 Q4
2 quarters
CINC
23
DELISTED
CinCor Pharma
CINC
$31M 1.5%
1,644,393
-90,900
-5% -$1.74M
2022 Q1
1 quarter
OLMA icon
24
Olema Oncology
OLMA
$626M
$31M 1.5%
7,611,503
+200,000
+3% +$634K
2020 Q4
6 quarters
FDMT icon
25
4D Molecular Therapeutics
FDMT
$604M
$28M 1.35%
4,007,413
+1,342,892
+50% +$13.1M
2020 Q4
6 quarters

Similar funds

BVF Inc's Q2 2022 Portfolio in Review

As of Q2 2022, BVF Inc held 87 positions worth $2.07B, down 17% from $2.5B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

BVF Inc deployed $142M of net new capital in Q2 2022, opening 6 new positions and adding to 22 existing holdings. Its largest new stake was MoonLake Immunotherapeutics: 21,751,284 shares worth $114M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Protagonist Therapeutics, an estimated $37.2M trimmed.

  • BVF Inc's largest Q2 2022 buy was MoonLake Immunotherapeutics: 21,751,284 shares worth $114M.
  • BVF Inc added most to Centessa Pharmaceuticals in Q2 2022, an estimated $32.9M increase.
  • BVF Inc's biggest Q2 2022 reduction was Protagonist Therapeutics, cutting an estimated $37.2M.
  • BVF Inc fully exited argenx in Q2 2022, selling an estimated $100M.
  • BVF Inc's ten largest holdings make up 44% of its $2.07B portfolio in Q2 2022.
  • BVF Inc opened 6 new positions and closed 8 in Q2 2022.
  • BVF Inc's portfolio value fell 17% quarter-over-quarter to $2.07B.

Based on BVF Inc's 13F filing for Q2 2022, filed 15 Aug 2022.